306 related articles for article (PubMed ID: 33226665)
1. Sildenafil beyond erectile dysfunction and pulmonary arterial hypertension: Thinking about new indications.
Ala M; Mohammad Jafari R; Dehpour AR
Fundam Clin Pharmacol; 2021 Apr; 35(2):235-259. PubMed ID: 33226665
[TBL] [Abstract][Full Text] [Related]
2. Phosphodiesterase Type-5 Inhibitor Prescription Patterns in the United States Among Men With Erectile Dysfunction: An Update.
Mulhall JP; Chopra I; Patel D; Hassan TA; Tang WY
J Sex Med; 2020 May; 17(5):941-948. PubMed ID: 32144034
[TBL] [Abstract][Full Text] [Related]
3. Beyond Erectile Dysfunction: cGMP-Specific Phosphodiesterase 5 Inhibitors for Other Clinical Disorders.
Samidurai A; Xi L; Das A; Kukreja RC
Annu Rev Pharmacol Toxicol; 2023 Jan; 63():585-615. PubMed ID: 36206989
[TBL] [Abstract][Full Text] [Related]
4. [Phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: past, present and future].
Gamidov SI; Ovchinnikov RI; Popova AY; Izhbaev SK
Urologiia; 2017 Apr; (1):103-107. PubMed ID: 28394532
[TBL] [Abstract][Full Text] [Related]
5. [Current role of sildenafil in the management of erectile dysfunction].
Akhvlediani ND; Matyukhov IP
Urologiia; 2018 May; (2):142-146. PubMed ID: 29901310
[TBL] [Abstract][Full Text] [Related]
6. Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction: Pharmacology and Clinical Impact of the Sildenafil Citrate Orodispersible Tablet Formulation.
Scaglione F; Donde S; Hassan TA; Jannini EA
Clin Ther; 2017 Feb; 39(2):370-377. PubMed ID: 28139291
[TBL] [Abstract][Full Text] [Related]
7. Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction.
Mulhall JP; McLaughlin TP; Harnett JP; Scott B; Burhani S; Russell D
J Sex Med; 2005 Nov; 2(6):848-55. PubMed ID: 16422809
[TBL] [Abstract][Full Text] [Related]
8. Useful Implications of Low-dose Long-term Use of PDE-5 Inhibitors.
Mostafa T
Sex Med Rev; 2016 Jul; 4(3):270-284. PubMed ID: 27871960
[TBL] [Abstract][Full Text] [Related]
9. Comparison of clinical trials with sildenafil, vardenafil and tadalafil in erectile dysfunction.
Doggrell SA
Expert Opin Pharmacother; 2005 Jan; 6(1):75-84. PubMed ID: 15709885
[TBL] [Abstract][Full Text] [Related]
10. Sildenafil for Pulmonary Arterial Hypertension.
Bhogal S; Khraisha O; Al Madani M; Treece J; Baumrucker SJ; Paul TK
Am J Ther; 2019; 26(4):e520-e526. PubMed ID: 30946047
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of tadalafil in men with erectile dysfunction naïve to phosphodiesterase 5 inhibitor therapy compared with prior responders to sildenafil citrate.
Broderick GA; Donatucci CF; Hatzichristou D; Torres LO; Valiquette L; Zhao Y; Loughney K; Sides GD; Ahuja S
J Sex Med; 2006 Jul; 3(4):668-675. PubMed ID: 16839323
[TBL] [Abstract][Full Text] [Related]
12. Direct comparison of tadalafil with sildenafil for the treatment of erectile dysfunction: a systematic review and meta-analysis.
Gong B; Ma M; Xie W; Yang X; Huang Y; Sun T; Luo Y; Huang J
Int Urol Nephrol; 2017 Oct; 49(10):1731-1740. PubMed ID: 28741090
[TBL] [Abstract][Full Text] [Related]
13. Erectile Dysfunction Drugs Changed the Protein Expressions and Activities of Drug-Metabolising Enzymes in the Liver of Male Rats.
Sheweita SA; Wally M; Hassan M
Oxid Med Cell Longev; 2016; 2016():4970906. PubMed ID: 27800121
[TBL] [Abstract][Full Text] [Related]
14. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond.
Ghofrani HA; Osterloh IH; Grimminger F
Nat Rev Drug Discov; 2006 Aug; 5(8):689-702. PubMed ID: 16883306
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular parameter changes in patients with erectile dysfunction using pde-5 inhibitors: a study with sildenafil and vardenafil.
Pomara G; Morelli G; Pomara S; Taddei S; Ghiadoni L; Dinelli N; Travaglini F; Dicuio M; Mondaini N; Salvetti A; Selli C
J Androl; 2004; 25(4):625-9. PubMed ID: 15223851
[TBL] [Abstract][Full Text] [Related]
16. Review of phosphodiesterases in the urogenital system: new directions for therapeutic intervention.
Montorsi F; Corbin J; Phillips S
J Sex Med; 2004 Nov; 1(3):322-36. PubMed ID: 16422964
[TBL] [Abstract][Full Text] [Related]
17. Novel phosphodiesterase-5 inhibitors: current indications and future directions.
Sharma R
Indian J Med Sci; 2007 Dec; 61(12):667-79. PubMed ID: 18174638
[TBL] [Abstract][Full Text] [Related]
18. Comparison of phosphodiesterase type 5 (PDE5) inhibitors.
Wright PJ
Int J Clin Pract; 2006 Aug; 60(8):967-75. PubMed ID: 16780568
[TBL] [Abstract][Full Text] [Related]
19. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.
Montani D; Chaumais MC; Savale L; Natali D; Price LC; Jaïs X; Humbert M; Simonneau G; Sitbon O
Adv Ther; 2009 Sep; 26(9):813-25. PubMed ID: 19768639
[TBL] [Abstract][Full Text] [Related]
20. Erectile dysfunction drugs altered the activities of antioxidant enzymes, oxidative stress and the protein expressions of some cytochrome P450 isozymes involved in the steroidogenesis of steroid hormones.
Sheweita SA; Meftah AA; Sheweita MS; Balbaa ME
PLoS One; 2020; 15(11):e0241509. PubMed ID: 33166302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
